The Latest Breakthroughs in LG-IR-NMIBC (2025)
Update: 2025-09-26
Description
The Latest Breakthroughs in LG-IR-NMIBC (2025)
CME Available: auau.auanet.org/node/43689
After participating in this CME activity, participants will be able to:
1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes.
2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns.
3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments.
4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval).
5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies.
6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery.
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
UroGen Pharma, Inc.
CME Available: auau.auanet.org/node/43689
After participating in this CME activity, participants will be able to:
1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes.
2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns.
3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments.
4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval).
5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies.
6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery.
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
UroGen Pharma, Inc.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
